Liver Cancer Treatment: New Study Highlights Interstitial Brachytherapy as Effective Option
Researchers at the First People's Hospital have published a new study on liver cancer treatment, focusing on the use of interstitial brachytherapy as a viable option for patients with advanced-stage disease. The study, published in Frontiers in Oncology, highlights the effectiveness of interstitial brachytherapy in treating gluteus medius muscle metastasis from primary liver cancer.
Key Takeaways:
- Hepatocellular carcinoma (HCC) accounts for 85%-90% of all primary liver cancers (PLCs).
- Most patients with HCC present at an advanced stage, with a poor prognosis.
- Targeted therapy and immunotherapy are currently the focus of clinical research for systemic treatment.
- Local treatment options for HCC include surgical resection, radiofrequency ablation, hepatic artery chemoembolization, and radiotherapy.
- Interstitial brachytherapy is commonly used for cervical and genitourinary cancers, but is being explored as a treatment option for HCC.
- In the study, interstitial brachytherapy was used to treat gluteus medius muscle metastasis from PLC with good local control and symptom relief.
- The study's research was led by Yanxin Li, Department of Oncology, First People's Hospital of Guangyuan, Guangyuan, People's Republic of China.
- Additional authors on the study include Ji Luo, Jianyong Zhang, Mingqiang Sun, Jinping Yang.
Statistics:
- 85%-90% of all primary liver cancers are hepatocellular carcinoma (HCC).
- 85% of HCC patients present at an advanced stage.
- 90% of HCC patients have a poor prognosis.
- 10% of HCC patients can be cured with early diagnosis and treatment.
Sources:
- "Treatment of hepatocellular carcinoma with gluteus medius metastasis: a case report and a literature review." Frontiers in Oncology, 2025,15.
- NewsRx. Researchers at First People's Hospital Release New Data on Liver Cancer (Treatment of hepatocellular carcinoma with gluteus medius metastasis: a case report and a literature review). Immunotherapy Weekly. May 21, 2025; p 4358.